Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TT-10 |
Synonyms | |
Therapy Description |
TT-10 acts as an antagonist to the adenosine receptor A2AR, potentially leading to inhibition of tumor growth and enhanced antitumor immune response (Cancer Res (2022) 82 (12_Supplement): 3454) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TT-10 | TT10|TT 10 | Adenosine Targeting 23 | TT-10 acts as an antagonist to the adenosine receptor A2AR, potentially leading to inhibition of tumor growth and enhanced antitumor immune response (Cancer Res (2022) 82 (12_Supplement): 3454) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04969315 | Phase Ib/II | TT-10 | TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | Active, not recruiting | USA | 0 |